GLP-2 (Glucagonlike Peptide-2) and Blood Flow

The Role of GLP-2 in Univercal Changes in Blood Flow in Humans

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00540215

Enrollment

Registered

2007-10-05

Start date

2007-10-31

Completion date

2008-02-29

Last updated

2011-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Regional Blood Flow

Brief summary

It is the study aim to investigate the effect of glp-2 on blood flow in humans. we wish to study eventual changes in renal blood flow, carotic blood flow and cardiac out put. GLP-2 will be administered subcutaneously, and the effect monitored by doppler ultra sound scannings and cotinuesly measuring of cardiac out put and blood pressure. The study will include 15 healhty volunteers, 10 wil receive 450 nmol GLP-2 and 5 will receive 1 ml of isotonic saline (as baseline reference).

Detailed description

se the above

Interventions

OTHERGlucagonlike peptide

450 nmol native form, synthetic

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

20 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Age 20-60 * Healthy * No medication * Not pregnant

Exclusion criteria

* All of the persons not meeting the abowe mentioned criteria

Design outcomes

Primary

Measure	Time frame
effect of glp-2	during study

Secondary

Measure	Time frame
potential new ideas for further studies	months to years

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026